The Latest Breaking News from Recursion Pharmaceuticals

Is Nvidia’s investment a good reason to buy these stocks?

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive supercomputer will give it the edge to dominate the sector.

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity.

Down 76% from all-time highs, is this AI-powered drug stock a good buy right now?

These under-the-radar companies may offer greater long-term rewards.

You're doing something right if your company is worth $2.6 trillion like Nvidia. And it's worth looking at the companies Nvidia invests in.

Morgan Stanley is betting on these stocks to benefit from the AI megatrend.

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.